Paper Details

  1. Home
  2. Paper Details

miR-134 increases the antitumor effects of cytarabine by targeting Mnks in acute myeloid leukemia cells.

Author: ChenKankan, ChenYue, ChenZhi, DingBanghe, HeZhengmei, ShiYuye, WangChunling, YuLiang

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

MicroRNA-134 (miR-134) plays a pivotal role in acute myeloid leukemia (AML) resistance to cytarabine (Ara-C). A study found that miR-134 was significantly downregulated in human multidrug-resistant leukemia cells and relapsed/refractory AML patient samples. Overexpression of miR-134 sensitized cells to Ara-C and enhanced the ability of Ara-C to induce apoptosis.
Paper Details　
Original Abstract of the Article :
The relapse and resistance to cytarabine (Ara-C) therapy is still a dominating obstacle to the successful clinical treatment of acute myeloid leukemia (AML). Recent studies have shown that dysregulation of miRNAs might modulate the resistance of cancer cells to anticancer drugs; yet, the mechanism i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975600/

データ提供：米国国立医学図書館（NLM）

miR-134: A Potential Weapon against AML

Acute myeloid leukemia (AML) is a formidable foe, a relentless cancer that often proves resistant to treatment. This study delves into the complex world of microRNAs, investigating the potential of miR-134 to enhance the effectiveness of cytarabine (Ara-C) therapy for AML. The authors found that miR-134 was significantly downregulated in multidrug-resistant leukemia cells and relapsed/refractory AML patient samples, suggesting its potential role in drug resistance. Their research revealed that miR-134 overexpression sensitized AML cells to Ara-C, inhibiting cell colony formation and promoting apoptosis.

Targeting miR-134 for AML Treatment

This study presents a promising avenue for improving AML treatment. The authors discovered that miR-134 plays a crucial role in AML Ara-C resistance by targeting Mnks, a protein involved in cell growth and survival. These findings suggest that modulating miR-134 expression could potentially enhance the effectiveness of Ara-C therapy.

Hope for AML Patients

This research offers a glimmer of hope for AML patients. The potential of miR-134 to sensitize AML cells to Ara-C provides a new target for therapeutic intervention. Further research is needed to explore the clinical applications of this promising microRNA.

Dr.Camel's Conclusion

This study, like a spring of water in a parched desert, offers a potential solution to the challenge of AML drug resistance. It underscores the importance of exploring microRNAs as a new frontier in cancer therapy.

Date :
  1. Date Completed n.d.
  2. Date Revised 2020-10-01
Further Info :

Pubmed ID

29872325

DOI: Digital Object Identifier

PMC5975600

Related Literature

Article Analysis
・Effects of cytarabine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.